This project tested the hypothesis that a 'second-generation' ultrasound (US) contrast agent (Optison™), offering extended echogenicity over that of its 'first-generation' predecessor (Albunex®), would have the greater potential for sonolysis of human erythrocytes in vitro. Whole human blood, obtained from apparently healthy donors, was anticoagulated and subsequently exposed in vitro to US in the presence of one of each or neither of the two US contrast agents. The US exposures were for 30 s and involved frequency (1.0, 2.2 and 3.4 MHz) and amplitude (∼2.8 to 0.38 MPa P-) regimens; pulse duration (200 μs) and interpulse interval (20 ms) were held constant. The data supported the hypothesis, with an overall ratio of ∼2.5 for relative extent of background-corrected US-induced hemolysis of the Optison™/Albunex® regimens. Passive cavitation detection analyses corroborated the results obtained with hemolysis.
- Hemolysis in vitro
- Passive cavitation detection
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Acoustics and Ultrasonics